GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genelux Corp (NAS:GNLX) » Definitions » Price-to-Tangible-Book

Genelux (Genelux) Price-to-Tangible-Book : 6.68 (As of May. 14, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Genelux Price-to-Tangible-Book?

As of today (2024-05-14), Genelux's share price is $3.755. Genelux's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $0.56. Hence, Genelux's Price to Tangible Book Ratio of today is 6.68.

The historical rank and industry rank for Genelux's Price-to-Tangible-Book or its related term are showing as below:

GNLX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.88   Med: 19.27   Max: 19.27
Current: 5.14

During the past 4 years, Genelux's highest Price to Tangible Book Ratio was 19.27. The lowest was 4.88. And the median was 19.27.

GNLX's Price-to-Tangible-Book is ranked worse than
72.62% of 1220 companies
in the Biotechnology industry
Industry Median: 2.71 vs GNLX: 5.14

A closely related ratio is called PB Ratio. As of today, Genelux's share price is $3.755. Genelux's Book Value per Sharefor the quarter that ended in Mar. 2024 was $0.56. Hence, Genelux's P/B Ratio of today is 6.68.


Genelux Price-to-Tangible-Book Historical Data

The historical data trend for Genelux's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genelux Price-to-Tangible-Book Chart

Genelux Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - - 19.27

Genelux Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 252.18 37.39 27.18 19.27 11.44

Competitive Comparison of Genelux's Price-to-Tangible-Book

For the Biotechnology subindustry, Genelux's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genelux's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genelux's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Genelux's Price-to-Tangible-Book falls into.



Genelux Price-to-Tangible-Book Calculation

Genelux's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=3.755/0.562
=6.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Genelux Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Genelux's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Genelux (Genelux) Business Description

Traded in Other Exchanges
N/A
Address
2625 Townsgate Road, Suite 230, Westlake Village, CA, USA, 91361
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
Executives
Tony Yu officer: VP, Clinical Trial Operations C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
John Thomas director C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Aladar Szalay 10 percent owner C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Sean Ryder officer: General Counsel C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
John W Smither director C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Lourie S. Zak officer: Chief Financial Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Thomas Zindrick director, officer: President and CEO C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE. 230, WESTLAKE VILLAGE CA 91361
Joseph Cappello officer: VP, Pharmaceutical Development C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Doug Samuelson officer: Chief Financial Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Caroline Jewett officer: Head of Quality C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Ralph Smalling officer: Head of Regulatory C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Qian Zhang officer: Associate VP, Research C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Mary Mirabelli director C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Paul Scigalla officer: Chief Medical Officer C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361